THE USE OF TC-99(M)-TECHNEGAS IN THE INVESTIGATION OF PATIENTS WITH PULMONARY THROMBOEMBOLISM

Pulmonary embolism remains a major cause of morbidity and mortality, being responsible for an estimated 200,000 deaths per annum in the USA and 21,000 per annum in the UK. Lung scintigraphy is in many instances the investigation of choice in suspected pulmonary thromboembolism. A normal perfusion lung scan excludes pulmonary embolism. An abnormal perfusion scan, while being sensitive, is of low specificity for the diagnosis of pulmonary embolism and needs to be complemented with a ventilation study. Lung ventilation has been studied using inert gases of radiolabelled aerosols. The new radiopharmaceutical Tc-99(m)-Technegas is a suspension of (9)9Tc(m)-labelled, ultrafine, carbon particles produced in an atmosphere of high-purity argon. The size of the particles is of the order of 0.00-0.2 mu m, which assures good peripheral penetration and alveolar deposition. After inhalation, static images in multiple projections may be acquired. The resultant images are of excellent technical quality and several publications have shown the value of Technegas images as an adjunct to perfusion imaging in suspected pulmonary thromboembolism. Studies comparing Technegas images with other ventilatory radiopharmaceuticals have in the majority of instances reported comparable diagnostic qualities.